All In Biotech

Drug Trial Radar · NCT07139873

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

A Phase 3, Open-Label, Randomized, Multicenter Study to Evaluate Anti-tumor Efficacy of DZD8586 Versus Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Sep 8, 2025

Primary completion

Jan 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Dizal PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy. Primary objective of this study is to assess the efficacy using progression free survival assessed by independent review committee as primary endpoint. Approximately 250 participants are estimated to be randomized into the study.

Conditions

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

  • DZD8586Drug

    Orally, 50 mg, once daily until treatment discontinuation criterion is met.

  • BendamustineDrug

    Administered intravenously

  • IdelalisibDrug

    Administered orally

  • RituximabDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) assessed by Independent Review Committee (IRC)Time frame: Approximately 36 Months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.